VanEck Associates
ADMA icon

VanEck Associates’s ADMA Biologics ADMA Stock Holding History

VanEck Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-220,989
Closed -$4.38M – 1395
2025
Q1 		$4.38M Buy
220,989
+21,359
+11% +$369K 0.01% 749
2024
Q4 		$3.42M Buy
+199,630
New +$3.76M ﹤0.01% 824

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

VanEck Associates's ADMA Position: Q2 2025 in Review

VanEck Associates sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 220,989 shares — an estimated $4.38M sold.

VanEck Associates first reported a position in ADMA in Q4 2024 and held it in 2 quarters. The position peaked at $4.38M in Q1 2025. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • VanEck Associates reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • VanEck Associates sold 220,989 ADMA Biologics shares in Q2 2025, an estimated $4.38M.
  • VanEck Associates first reported a position in ADMA Biologics in Q4 2024 and held it in 2 quarters.
  • VanEck Associates's ADMA Biologics position peaked at $4.38M in Q1 2025.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on VanEck Associates's 13F filing for Q2 2025, filed 14 Aug 2025.